I'm ready to run,,you've almost convinced me to run..I'm in my track stance..Oh Wait!
you've haven't told me why I should run...hurry up before I cramp up!
This could be two years old...there is no reference at to what this is, or when...but thanks for finding
it,,and posting it,,,as it's worth what we paid for it...
Only if you don't understand either the science, or the actual marketing returns, could one make
up their own numbers. Most if us have no true understanding as to actually how many actual
patients their are for this drug, or what level of market penetrations the drug could achieve. But
there are professionals out there that do have at their disposal the assets to ascertain these true
projections. I firmly believe this stock is moving up on the pretense of those folks knowing an
investing based on their workups. Too many dollars are going into this company's stock to be
majorativley speculative. I also do believe this company either through partnerships, or a buyout
will not exist as a standalone by year end..
I personally don't agree with your assessment. I don't know of any reason INSM would have to do
any further trials...The drug has gone through the entire regiment of the trial process, and was
successful (except for MMD, a trial no drug could pass), and was approved for use in short stature,
and could have been prescribed for other indications off label..The only issue standing in the way
of Iplex being brought to market, other than management deciding to invest the resources to do so,
would be the patent infringement lawsuit. INSM didn't try to find another process for creating Iplex,,
a laboratory process, and therefor IPLEX was found to infringe on Tericia's patents...This issue
is moot in 2017, if my memory serves me correct, and we should see some interest in it prior to that.
I had to look to see if it really was you..I've seen the levonchikio..levonchioki, and a couple others.
Back to business,,,someone wants a position here..and they want it now...
You're an idiot..she's still with the company...doing a PROFESSIONAL handoff..
Is staying with the company as a consultant...find something new to focus on..
I got it..the CEO likes peanut butter...that's big!!!!
Amazing...in all my years I have never seen anything like this..I can understand a basher
team doing this,,but one person..picture this idiot...TYPING FURIOUSLY!!!!!!!!!!!!! it is
funny as hell..
This is really eye opening..first of all, it tells you how many ID's one individual can control. Secondly
it shows you how desperate ONE person can be..This person has no short position..make no mistake,
this is the work of someone that takes satisfaction out of being noisy..kinda like screamin.."Look at
me, I demand it"....But the company has received good news..you can't bury that fact..
Insmed Incorporated (the "Company") announced today that the U.S. Food and Drug Administration (the "FDA") granted ARIKAYCE�, or liposomal amikacin for inhalation, Breakthrough Therapy Designation for the treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease who are treatment refractory. This designation is based on findings from the Company's U.S. phase 2 clinical trial of ARIKAYCE to treat NTM lung infections. The Company has plans to meet with the FDA to discuss the regulatory pathway for ARIKAYCE